Teitur Trophics announces successful results from Phase I clinical trial of first-in-class Parkinson’s disease peptide TT-P34
- Study shows TT-P34 is safe and well tolerated in healthy volunteers and patients with early-stage Parkinson’s disease (PD), with pharmacokinetics confirming robust CNS exposure
- Early biomarker signals are consistent with pathway modulation in the brain
- Teitur is planning to start a Phase II clinical trial of TT-P34 in PD in 2027
Aarhus, Denmark, September 10, 2026: Teitur Trophics (“Teitur”), a biotechnology company developing novel neuroprotective peptides for neurodegenerative diseases, today announced successful results from its Phase I clinical trial of its lead asset TT-P34 in healthy volunteers and patients with early-stage Parkinson’s disease (PD).
